http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ahmed Abu-Zaid,Osama Alomar,Nora F AlNaim,Fatimah Shakir Abualsaud,Mohammed Ziad Jamjoom,Latifa F AlNaim,Abdullah AMA Almubarki,Saeed Baradwan,Saud Abdullah Saud Aboudi,Faisal Khalid Idris,Meshael Fod 대한산부인과학회 2022 Obstetrics & Gynecology Science Vol.65 No.2
We aimed to perform a systematic review and meta-analysis of all randomized placebo-controlled trials (RCTs)that examined the analgesic benefits of preemptive pregabalin among patients undergoing minimally invasivehysterectomy. Five major databases were systematically screened from inception until August 29, 2021 Relevantstudies were evaluated for risk of bias. Endpoints were analyzed using the random-effects model and pooled asthe mean difference or risk ratio with a 95% confidence interval. Four studies with seven treatment arms met theinclusion criteria. The total sample size was 304 patients: 193 and 111 patients were allocated to the pregabalin andplacebo groups, respectively. Overall, the included studies revealed a low risk of bias. The summary results revealedthat the mean postoperative pain scores at rest were significantly lower in the pregabalin group than in the controlgroup at 0, 2, 4, 6, 12, and 24 hours. Moreover, the mean postoperative pain scores on movement/coughing weresignificantly lower in the pregabalin group than in the control group at 12 and 24 hours. The rate of patients whowere opioid-free postoperatively was significantly higher in the pregabalin group than in the control group. Therewas no significant difference between the groups in terms of the mean postoperative time to first rescue analgesicand the rates of adverse events. Compared with placebo, preemptive pregabalin was largely safe, and was correlatedwith superior analgesic effects in terms of lower postoperative pain scores and higher opioid-sparing effects. Additional RCTs are needed to confirm these findings.
Ahmed Abu-Zaid,Saeed Baradwan,Ehab Badghish,Rayan AlSghan,Ahmed Ghazi,Bayan Albouq,Khalid Khadawardi,Nora F AlNaim,Latifa F AlNaim,Meshael Fodaneel,Fatimah Shakir Abualsaud,Mohammed Ziad Jamjoom,Abdul 대한산부인과학회 2022 Obstetrics & Gynecology Science Vol.65 No.5
To perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) that evaluated the efficacyand safety of prophylactic tranexamic acid (TXA) versus a control (placebo or no treatment) during hysterectomy forbenign conditions. Six databases were screened from inception to January 23, 2022. Eligible studies were assessed forrisk of bias. Outcomes were summarized as weighted mean differences and risk ratios with 95% confidence intervalsin a random-effects model. Five studies, comprising six arms and 911 patients were included in the study. Two andthree studies had an overall unclear and low risk of bias, respectively. Estimated intraoperative blood loss, requirementfor postoperative blood transfusion, and requirement for intraoperative topical hemostatic agents were significantlyreduced in a prophylactic TXA group when compared with a control group. Moreover, postoperative hemoglobinlevel was significantly higher in the prophylactic TXA group than in the control group. Conversely, the frequencyof self-limiting nausea and vomiting was significantly higher in the prophylactic TXA group than in the control group. There were no significant differences between the groups in terms of surgery duration, hospital stay, and diarrhearate. All the RCTs reported no incidence of major adverse events in either group, such as mortality, thromboembolicevents, visual disturbances, or seizures. There was no publication bias for any outcome, and leave-one-out sensitivityanalyses demonstrated stability of the findings. Among patients who underwent hysterectomy for benign conditions,prophylactic TXA appeared largely safe and correlated with substantial reductions in estimated intraoperative bloodloss and related morbidities.